Hiroshi Nagabukuro - Extra Value Generat Drug Discovery Unit, Takeda Pharmaceut Co

基本信息

浏览量：30

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 52 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A Phase 2 Randomized, Double-Blind Trial of ART-001, a Selective PI3Kα Inhibitor, for the Treatment of Slow-Flow Vascular Malformations

Michio Ozeki,Akira Tanaka,Kanako Kuniyeda,Taiki Nozaki,Akihiro Fujino,Tadashi Nomura,Naoto Uemura,Souichi Suenobu,Noriko Aramaki-Hattori,Ayato Hayashi,Aiko Kato,Hiro Kiyosue,Kotaro Imagawa,Munetomo Nagao,Fumiaki Shimizu,Junko Ochi,Saya Horiuchi,Tetsuji Ohyama, Haruhi Ando,Hiroshi Nagabukuro

Orphanet Journal of Rare Diseasesno. 1 (2025): 1-11

引用0浏览0WOS引用

The Prospective Natural History Study of Patients with Intractable Venous Malformation and Klippel-Trenaunay Syndrome to Guide Designing a Proof-of-Concept Clinical Trial for Novel Therapeutic Intervention

Akihiro Fujino,Kanako Kuniyeda,Taiki Nozaki,Michio Ozeki,Tetsuji Ohyama,Iori Sato,Kiyoko Kamibeppu,Akira Tanaka,Naoto Uemura, Kazuhiro Kanmuri, Kenji Nakamura, Fumiaki Kobayashi,Souichi Suenobu,Tadashi Nomura,Ayato Hayashi,Munetomo Nagao,Aiko Kato,Noriko Aramaki-Hattori,Kotaro Imagawa,Kosuke Ishikawa,Junko Ochi,Saya Horiuchi,Hiroshi Nagabukuro

LYMPHATIC RESEARCH AND BIOLOGYno. 1 (2024): 27-36

引用0浏览0WOS引用

Safety, Pharmacokinetics, and Pharmacodynamics of ART-648, a PDE4 Inhibitor in Healthy Subjects: A Randomized, Placebo-Controlled Phase I Study

Akira Tanaka,Hiroshi Nagabukuro,Kanako Kuniyeda, Haruhi Ando, Toshinori Higashi,Hirokazu Wakuda,Naoyuki Otani,Hideo Kudo,Masae Kuranari,Hidetoshi Furuie,Naoto Uemura

CTS-CLINICAL AND TRANSLATIONAL SCIENCE（2024）

引用0浏览0WOS引用

Urinary Liver-Type Fatty Acid Binding Protein is a Biomarker Reflecting Renal Damage and the Ameliorative Effect of Drugs at an Early Stage of Histone-Induced Acute Kidney Injury

Keiichi Ohata,Takeshi Sugaya, Hanh Nhung Nguyen, Karin Arai, Yuri Hatanaka,Kinuko Uno,Marika Tohma, Teppei Uechi, Keita Sekiguchi,Tsuyoshi Oikawa,Hiroshi Nagabukuro,Kanako Kuniyeda,Atsuko Kamijo-Ikemori,Noriko Suzuki-Kemuriyama,Dai Nakae,Eisei Noiri,Katsuhiro Miyajima

NEPHROLOGY（2024）

引用2浏览0WOS引用

A Randomized, Placebo‐controlled Study to Evaluate Safety and Pharmacokinetics of ART‐001 with a Novel Oral Pediatric Formulation in Healthy Subjects

Akira Tanaka,Naoto Uemura,Kanako Kuniyeda, Haruhi Ando, Toshinori Higashi,Hiroshi Nagabukuro

CTS-CLINICAL AND TRANSLATIONAL SCIENCE（2023）

引用1浏览0WOS引用

Urinary Liver-Type Fatty Acid Binding Protein is Increased in the Early Stages of the Disease with a Risk of Acute Kidney Injury Induced by Histone

Keiichi Ohata,Takeshi Sugaya, Hanh Nhung Nguyen, Yuri Hatanaka,Kinuko Uno,Marika Tohma,Tsuyoshi Oikawa,Hiroshi Nagabukuro,Kanako Kuniyeda,Atsuko Kamijo-Ikemori,Noriko Suzuki-Kemuriyama,Dai Nakae,Eisei Noiri,Katsuhiro Miyajima

NEPHROLOGYno. 6 (2023): 345-355

引用3浏览0WOS引用

Drug Reprofiling and Repurposing: a State-of-the-art Public-Private Collaboration Model

Hiroshi NAGABUKURO,Naoto UEMURA

Translational and Regulatory Sciencesno. 2 (2020): 47-50

引用0浏览0引用

Use of Selective PGE2 Receptor Antagonists on Human Endometriotic Stromal Cells and Peritoneal Macrophages

Tomoko Makabe,Kaori Koga,Hiroshi Nagabukuro,Mari Asada,Erina Satake,Ayumi Taguchi,Arisa Takeuchi,Mariko Miyashita,Miyuki Harada,Tetsuya Hirata,Yasushi Hirota,Osamu Wada-Hiraike,Tomoyuki Fujii,Yutaka Osuga

Molecular Human Reproduction（2020）

引用7浏览0WOS引用

Anti-Metabolic, Anti-Inflammatory And Anti-Fibrotic Properties Of Art-648, A Novel Phosphodiesterase 4 Inhibitor As A Potential Clinical Candidate For Non-Alcoholic Steatohepatitis

Yuichiro Amano,Shuntarou Tsuchiya,Mitsuharu Matsumoto,Hikaru Ueno,Nobuhiro Nishigaki,Osamu Isono,Guido Hanauer,Kazumasa Miyawaki,Kimio Tohyama,Hirohisa Miyashita,Mayumi Imai,Fumi Shimizu,Akira Tanaka,Hiroshi Nagabukuro

JOURNAL OF HEPATOLOGY（2019）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn